DanielleA.ShaferDO

Oncology • Fairfax, VA

Hematologic Oncology

Assistant Professor, Virginia Commonwealth University

Join to view full profile

Dr. Shafer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shafer's full profile

Already have an account?

Office
8081 Innovation Park Dr
Fairfax, VA 22031
Phone+1 571-472-4724

Fax+1 571-472-0241

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Loyola University Medical CenterResidency, Internal Medicine, 1999 - 2003
Chicago College of Osteopathic Medicine at Midwestern UniversityClass of 1999

Certifications & Licensure

VA State License 2013 - 2026
IL State License 1999 - 2014
PA State License 2003 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma Start of enrollment: 2009 Jan 01
Terminated
Phase 2
Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer Start of enrollment: 2012 Jun 01
Completed
Phase 2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

9 citations
Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies.
Danielle Shafer, Amanda B Kagan, Michelle A Rudek, Maciej Kmieciak, Mary Beth Tombes
Cancer Chemotherapy and Pharmacology. 2023-03-01
1 citations
Identification of a Cryptic t(8;20;21)(q22;p13;q22) Resulting in RUNX1T1/RUNX1 Fusion in a Patient with Newly Diagnosed Acute Myeloid Leukemia.
Erica L. Macke, Reid G. Meyer, Nicole L. Hoppman, Rhett P. Ketterling, Patricia T. Greipp
Laboratory Medicine. 2021-11-17
5 citations
Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome.
Beata Holkova, Danielle Shafer, Victor Yazbeck, Sandeep S. Dave, Prithviraj Bose
Leukemia & Lymphoma. 2021-04-16